These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 28177435)

  • 21. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple mutations of lung squamous cell carcinoma shared common mechanisms.
    Li Q; Hou J; Hu Z; Gu B; Shi Y
    Oncotarget; 2016 Nov; 7(48):79629-79636. PubMed ID: 27835590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
    Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Front Immunol; 2021; 12():665407. PubMed ID: 34177903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
    Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
    Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of eight immune-related genes on survival in patients with lung squamous cell carcinoma.
    Wu H; Huang S; Zhuang W; Qiao G
    Biomark Med; 2021 Mar; 15(4):295-306. PubMed ID: 33590774
    [No Abstract]   [Full Text] [Related]  

  • 29. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
    Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
    Ono A; Terada Y; Kawata T; Serizawa M; Isaka M; Kawabata T; Imai T; Mori K; Muramatsu K; Hayashi I; Kenmotsu H; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Akiyama Y; Sugino T; Ohde Y; Yamaguchi K; Takahashi T
    Cancer Med; 2020 Jul; 9(13):4864-4875. PubMed ID: 32400056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
    Wang K; Li Y; Wang J; Chen R; Li J
    Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
    Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
    J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma.
    Hao B; Dong H; Xiong R; Song C; Xu C; Li N; Geng Q
    Comput Biol Med; 2024 Mar; 171():108183. PubMed ID: 38422959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of an individualized immune prognostic model in stage I-III lung squamous cell carcinoma.
    Yang QF; Wu D; Wang J; Ba L; Tian C; Liu YT; Hu Y; Liu L
    Sci Rep; 2021 Jun; 11(1):12727. PubMed ID: 34135424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.